Drug Trial Radar · NCT05841381
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Last checked: Nov 19, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
876
Planned (sponsor's estimate)
Start
May 6, 2023
Primary completion
May 6, 2028
Study completion May 6, 2033
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, phase III study evaluating the efficacy and safety of Pyrotinib in Combination With Trastuzumab and paclitaxel in patients HER2 Positive and lymph node negative invasive Breast Cancer
Conditions
- Breast Cancer
Interventions
PyrotinibDrug
pyrotinib: 400mg orally daily for 1 year
TrastuzumabDrug
8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
PaclitaxelDrug
80mg/m2 per week for a total of 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survivalTime frame: 5 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.